Alzheimer’s is the most common type of dementia. Music therapy can improve mood and cognitive performance in Alzheimer’s ...

Cassava Sciences' simufilam failed a Phase III trial for Alzheimer's disease, likely marking the end of a drug surrounded by ...

The active agent in the nasal spray, 2-bromopalmitate, carries a high risk of interfering with a number of processes, making ...

Stay alert with list of early signs and symptoms of dementia that disrupts daily life and may be a symptom of Alzheimer’s or ...

Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate ...

The International Working Group discussed diagnosing Alzheimer's disease among cognitively unimpaired individuals in a ...

Investigational simufilam failed to reduce cognitive or functional decline in Alzheimer's disease patients in the ReThink-ALZ ...

Gibbs spent his career helping people as a neurologist. He retired in 2013, and a couple years later, was diagnosed with ...

A new study from the University of Liverpool represents a significant step forward in scientists' understanding of ...

Alector has significant cash reserves but faces high cash burn, with no immediate catalysts and uncertain prospects for its ...

A decade ago, researchers introduced a new model for studying Alzheimer's disease. Known as "Alzheimer's in a dish," the ...

Tau behaves abnormally in the brain in people with Alzheimer’s disease. This latest study points to a reason why.